Its role Investor / Financier
Kemin Industries, Inc. is a privately held, family-owned global biotechnology company and manufacturer of specialty ingredients. Founded in 1961 in Des Moines, Iowa, by R.W. and Mary Nelson, it remains under the leadership of the Nelson family, with Dr. Christopher E. Nelson as President and CEO.
The company develops and produces over 500 innovative ingredients and solutions primarily for animal nutrition and health, pet food and rendering, food technologies, human nutrition and health, crop technologies, aquaculture, bio solutions, and textile enzymes. Key products include antioxidants, enzymes, probiotics, carotenoids, mold inhibitors, and functional additives that improve product quality, safety, shelf life, gut health, and sustainability across supply chains.
Kemin operates in more than 90 countries with manufacturing facilities in the United States, Belgium, Brazil, China, India, Italy, Singapore, South Africa, and elsewhere. It serves customers in over 120 countries and employs several thousand people globally. The company emphasizes science-driven innovation, customer partnerships, and environmental responsibility, including the use of renewable energy and reduced carbon footprints.
Positioned as a leader in the ingredients sector, Kemin focuses on transforming the quality of life for people, pets, animals, plants, and the planet through sustainable, high-quality solutions in food, feed, health, and industrial applications.
chemXplore tracks 1 project involving Kemin Industries.
Renewed partnership extends supply of French-made, bio-based potassium-rich fertilizer for high-value crop formulations, strengthening local potassium availability.
Plant passed 1,000 t of bio-based acids; capacity reached 30–40% after June works; process held up during heat/water stress; aims to double NEOXY H2 2026 revenue vs H1.
NEOXY plant generated ~€1M in early 2026, production in the hundreds of tonnes, capacity at 20%, and a June 2026 shutdown for reliability and optimisation.
The plant completed construction, began production, and delivered initial biobased acid lots. It aims for full capacity by 2023, targeting 16,000 tons annually and €35M in sales.
The financing will fund the first plant's design and development, advancing bio-based acid production technology for markets like cosmetics, nutrition, and fine chemicals.
active all projects
